Solutions

Clinical solutions

Blended Solutions Cardiac Safety Solutions Clinical & Scientific Operations Decentralised Clinical Trials Early Clinical Laboratories Medical Imaging Site & Patient Solutions Strategic Solutions

Consulting & Commercial

Asset Development Consulting Commercial Positioning Language Services Outcome Measures Real World Intelligence Regulatory Affairs Symphony Health data

Case studies
Reducing time to market, delivering on quality, providing deep therapeutic expertise and enhancing R&D ROI.

Technologies
Technology solutions from early phase through to post-marketing.
Sectors

Sectors

ICON provides its full range of clinical, consulting and commercial services across several industry sectors.

Read more

Biotech Government and Public Health Medical Device Pharmaceuticals

Biotech
Developing transformative therapies requires a flexible approach.

ICON and You
Partners making a difference.
Therapeutics

Therapeutics

Cardiovascular Central Nervous System Endocrine & Metabolic Disorders Hepatology Infectious Diseases Internal Medicine & Immunology Oncology

Cross-therapeutics

Biosimilars Cell and Gene Therapies Medical Device Pediatrics Rare & Orphan Diseases Vaccines Women's Health

Obesity
A focus on combination therapies requires appropriate obesity-specific trial designs, long-term follow-up studies and diverse patient recruitment.

Therapeutics insights
ICON's therapeutic experts contribute regularly to industry publications and the creation of thought leadership content. Read more.
Insights

Insights

Digital Disruption Patient Centricity Regulatory Intelligence Therapeutics insights Transforming Trials Value Based Healthcare Blog Videos Webinar Channel

Making sense of the rapidly changing biosimilars landscape
Strategies for adapting and achieving optimal market access

Building a comparative evidence base using network meta-analysis
Methods, implementation and reporting

From bottlenecks to breakthroughs
Human-centred strategies for faster study starts
News & Events

News & Events

ICON regularly contributes thought leadership to industry media publications and conferences, and has been recognised as one of the world’s leading Contract Research Organisations through a number of high-profile industry awards.

Read more

Press releases In the News Mediakit Awards Events Webinars Social media

Panel discussion: Flow cytometry in bioanalysis
26 March 2026. Register today.

ICH GCP E6(R3): Preparing for global implementation, assessing the impact, risk and requirements of the change
Watch the webinar.
About ICON

About ICON

Company history ICON at a glance ICON in Asia Pacific ICON in Latin America Leadership Quality

ICON for

Patients Volunteers Investigators Jobs & Careers Investors Suppliers

Sustainability, charity, inclusion and belonging
ICON Cares is our commitment to making a positive impact on our people, environment and our community.

ICON at a glance
Delivering successful outcomes across the clinical development lifecycle.

Careers
Investors
Contact
日本語
简体中文

Home
News & Events
Social media

Social media

Showing 421 - 432 of 1038 results for "*"

DHTs promise faster, more inclusive trials, but they must be implemented correctly. ICON’s latest whitepaper is a must-read for organizations looking to deploy digital measures in their trials. The whitepaper offers step...

26 Nov

View post

View webpage

ICON Plc

For the third and final article in our series, ICON’s regulatory expert Jeremy Tinkler discusses ISO 10993-1 in the context of risk estimation. This article looks at the upcoming revision of ISO 10993-1, which has spar...

26 Nov

View post

View webpage

ICON Plc

For the third and final blog in our series, we discuss ISO 10993-1 in the context of risk estimation. This blog looks at the upcoming revision of ISO 10993-1, which has sparked debate but now is in its final draft stag...

26 Nov

View post

View webpage

ICON Plc

Patient recruitment strategies need to evolve to ensure the best data from a wider range of patients. Meet ICON experts at #ASH25, booth \#2161 to learn how our strategic solutions and innovative methods help reduce pati...

26 Nov

View post

View webpage

ICON Plc

On December 8-10 at CVCT, speak with our cardio-metabolic drug development experts about how we’re helping to address the challenges of CV trials and improve outcomes through more efficient trial design, effective use of...

26 Nov

View post

View webpage

ICON Plc

26 Nov

View post

View webpage

ICON Plc

Join ICON for “Science on Tap” — an evening of discovery, discussion, and holiday cheer! Explore cutting-edge research in precision medicine and bioanalytical laboratory innovation with our expert scientists. If you ar...

25 Nov

View post

View webpage

ICON Plc

25 Nov

View post

View webpage

ICON Plc

High-risk medical devices and IVDs enter the JCA process in 2026. Are you prepared for what’s next? ICON’s whitepaper outlines what developers need to know—now. Read more: https://ow.ly/2wWF50XgHL8 #MedTech #IVD #JCA #H...

25 Nov

View post

View webpage

ICON Plc

25 Nov

View post

View webpage

ICON Plc

15+ years of healthcare data. Weekly and monthly. Metys®, from Symphony Health, and ICON plc company, gives you unmatched historical depth to track product trends, market shifts, and lifecycle performance with precisio...

25 Nov

View post

View webpage